Clinical trial
Phase 2 Study of the Safety and Pharmacokinetics of Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
NCT00721734 is registered in ClinicalTrials.gov with Amgen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2 Study of the Safety and Pharmacokinetics of Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function
- Lead sponsor
- Amgen
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 30, 2008
- Completion date
- November 30, 2012
- Enrollment
- 50 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.